Stocks and Investing Stocks and Investing
Wed, March 2, 2022
Tue, March 1, 2022

Jason Butler Maintained (ACAD) at Buy with Decreased Target to $35 on, Mar 1st, 2022


Published on 2024-10-27 19:53:49 - WOPRAI, Jason Butler
  Print publication without navigation


Jason Butler of JMP Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $42 to $35 on, Mar 1st, 2022.

Jason has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 6 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 3 analyists that currently disagree with Jason


  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
Contributing Sources